Results 221 to 230 of about 1,186,610 (361)

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

open access: yesArthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli   +4 more
wiley   +1 more source

The anatomical knowledge of Namibian school children

open access: yesAnatomical Sciences Education, EarlyView.
Abstract The public has limited knowledge of key organs and anatomical structures. The lack of anatomical knowledge and understanding can hinder time to access healthcare, quality of care, and treatment outcomes. The current study investigated the anatomical knowledge among Namibian children by comparing 8 school grades—4 to 12, which covers children ...
Adam M. Taylor   +3 more
wiley   +1 more source

Atypical Visually Guided Precision Grip Control in Middle‐Aged and Older Autistic Adults

open access: yesAutism Research, EarlyView.
ABSTRACT Sensorimotor impairments are well documented in autism spectrum disorder (ASD). However, little is known about how these difficulties present in middle‐aged and older autistic adults or how they relate to demographic factors and autistic traits.
Zheng Wang   +9 more
wiley   +1 more source

Out of the blue! Thyroid crisis

open access: hybrid, 2015
Mrunalini Parasa   +3 more
openalex   +1 more source

Recurrent spinal metastasis of a sporadic medullary carcinoma of the thyroid after radiation therapy: a case report and review of the literature [PDF]

open access: gold, 2015
Christopher Munoz‐Bendix   +6 more
openalex   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Home - About - Disclaimer - Privacy